We tested several histamine H 1 receptor (H 1 R) agonists and antagonists for their differences in binding affinities between human and guinea pig H 1 Rs transiently expressed in African green monkey kidney (COS-7) cells. Especially, the bivalent agonist histaprodifen-histamine dimer (HP-HA) shows a higher affinity for guinea pig than for human H 1 Rs. Based on the structure of HP-HA, we have further identified VUF 4669 [7-(3-(4-(hydroxydiphenylmethyl)piperidin-1-yl)propoxy)-4-oxochroman-2-carboxylic acid] as a guinea pig-preferring H 1 R antagonist, demonstrating that the concept of species selectivity is not limited to agonists. To delineate the molecular mechanisms behind the observed species selectivity, we have created mutant human H 1 Rs in which amino acids were individually replaced by their guinea pig H 1 R counterparts. Residue Asn 84 (2.61) in transmembrane domain (TM) 2 seemed to act as a selectivity switch in the H 1 R. Molecular modeling and sitedirected mutagenesis studies suggest that Asn 84 interacts with the conserved Tyr 458 (7.43) in TM7. Our data provide the first evidence that for some H 1 R ligands, the binding pocket is not only limited to TMs 3, 4, 5, and 6 but also comprises an additional pocket formed by TMs 2 and 7.
The biogenic amine histamine exerts its effects through binding and activation of four G protein-coupled receptors (GPCRs), the H 1 , H 2 , H 3 , and H 4 receptors. The H 1 receptor (H 1 R) regulates inflammatory and allergic responses and is successfully targeted by various drugs. H 1 R antagonists have been on the market since 1942 for the treatment of allergies, and newer, nonsedating second generation H 1 R antagonists are still the medication of choice to relief certain allergic symptoms (Hill et al., 1997) .
In contrast to the development of various potent H 1 R antagonists, the synthesis of selective and potent H 1 R agonists has not achieved the same success (Hill et al., 1997) . Only in 1995, 2-(3-trifluoromethylphenyl)histamine was discovered as the first selective H 1 R agonist with a potency equal to histamine as determined by the H 1 R-mediated guinea pig ileum contractions Zingel et al., 1995) . Recently, Elz et al. (2000) synthesized a series of compounds constituting a new class of highly active H 1 R agonists, the histaprodifens. Histaprodifen combines a histamine moiety linked at the 2-position with an ,-diphenylalkyl substituent, a characteristic of the H 1 R antagonist pharmacophore Zhang et al., 1997 ). Based on this new H 1 R agonist, "dimeric" histaprodifens were subsequently developed, consisting of a histaprodifen moiety linked at the N␣ position to another histamine moiety, for example (histaprodifen-histamine dimer, HP-HA) (Menghin et al., 2003) . Compared with histamine, the potency of HP-HA is reported to be 36-to 56-fold and 630-fold higher on guinea pig isolated ileum and trachea, respectively (Christophe et al., 2003; Seifert et al., 2003) .
Contrary to the potencies at either the guinea pig ileum and trachea or rat aorta (Elz et al., 2000; Christophe et al., 2003; Seifert et al., 2003) , the potencies of various histaprodifen analogs (histaprodifen, MeHP, HP-HA, and HP-HP) at human H 1 Rs are at best similar to the potency of the endogenous ligand histamine Bruysters et al., 2004) , indicating a potential species difference at the level of the H 1 R recognition of these H 1 R agonists.
In aminergic GPCRs, including the H 1 R, the ligand-binding pocket is thought to reside in a hydrophilic cleft formed by the seven transmembrane domains (TMs). Within the third TM (TM3), an aspartate (Asp) residue is a conserved feature among these aminergic GPCRs and is likely to make a direct contact with the protonated amine of aminergic ligands (Shi and Javitch, 2002) . Indeed, in the human H 1 R Asp 107 in TM3 (residue 3.32 according to the BallesterosWeinstein numbering) is part of the binding pocket of both H 1 R agonists and antagonists (Ohta et al., 1994; Moguilevsky et al., 1998; Nonaka et al., 1998; Bruysters et al., 2004) . Several additional amino acids in TM5 and TM6 are part of the H 1 R binding pocket of histamine: Lys 191 (5.39) (Leurs et al., 1995; Moguilevsky et al., 1998; Wieland et al., 1999; Gillard et al., 2002; Bruysters et al., 2004), Asn 198 (5.46) (Leurs et al., 1994; Ohta et al., 1994; Moguilevsky et al., 1995; Bruysters et al., 2004) , and Phe 435 (6.55) (Bruysters et al., 2004) are considered to accommodate the imidazole ring of histamine. The H 1 R antagonist binding pocket stretches deeper into the receptor protein and comprises the aromatic amino acids Trp 158 (4.56) (Wieland et al., 1999) and Phe 432 (6.52) (Wieland et al., 1999; Bruysters et al., 2004) . Recently, we studied the binding pocket of several histaprodifen analogs in the human H 1 R (Bruysters et al., 2004) . We demonstrated that histamine and the histamine moiety of histaprodifens bind to the human H 1 R in a similar orientation. Although the diphenylalkyl system of histaprodifen interacts with the H 1 R in an "antagonistic binding mode", i.e., interacting with Phe 432 (6.52) in TM6 (Bruysters et al., 2004) (Bruysters et al., 2004) .
We explored in this study the molecular basis of the observed species differences between human and guinea pig H 1 Rs by a combined approach of molecular modeling and site-directed mutagenesis. We reevaluated several H 1 R agonists and antagonists for their differences in affinity between human and guinea pig H 1 Rs by [ 3 H]mepyramine displacement studies. Based on our knowledge of the H 1 R binding site of the histaprodifens and the high (93%) level of sequence homology within the TM domains of the human and guinea pig H 1 Rs, we extended our approach to mutant human H 1 Rs in which selected amino acids were individually replaced by their guinea pig H 1 R counterparts. Using this strategy, we identified Asn 84 (2.61) in TM2 as the molecular basis for the observed species selectivity of certain H 1 R ligands and discuss the implications of these findings for future drug design.
Materials and Methods
Chemicals. Chloroquine diphosphate, DEAE-dextran (chloride form), histamine dihydrochloride, mepyramine (pyrilamine maleate), astemizole, ketotifen fumarate, 8R-lisuride, and terfenadine were purchased from Sigma-Aldrich (Bornem, Belgium). Oxatomide was obtained from MP Biomedicals (Zoetermeer, The Netherlands). Fexofenadine was purchased from Ultrafine Chemicals (Manchester, UK). VUF 4669 and VUF 8401 were synthesized at the Vrije Universiteit Amsterdam (Amsterdam, The Netherlands). Cetirizine dihydrochloride (Zyrtec) and loratadine were synthesized at UCB S.A. (Braine l'Alleud, Belgium).
Gifts of 2-(3-trifluoromethylphenyl)histamine dihydrogen maleate, histaprodifen (2-[2-(3,3-diphenylpropyl] imidazol-4-yl)ethanamine dihydrogen maleate), methylhistaprodifen (N␣-methyl-histaprodifen dihydrogen oxalate), histaprodifen-histaprodifen dimer trihydrogenoxalate and histaprodifen-histamine dimer (N␣-[2-(1H-imidazol-4yl)-ethyl]-histaprodifen) trihydrogenoxalate) (Dr. W. Schunack, Free University, Berlin, Germany), the cDNA encoding the human H 1 R (Dr. H. Fukui, University of Tokushima, Tokushima, Japan), and the expression vector pcDEF 3 (Goldman et al., 1996) Numbering Scheme of GPCRs. The indexing method introduced by Ballesteros and Weinstein (1995) was used throughout to identify amino acids in the TM regions. Each residue is identified by two numbers: the first number corresponds to the helix (1-7) in which the residue is located, and the second number indicates its position relative to the most conserved amino acid in that helix, arbitrarily assigned to 50. Numbers depicted in superscript correspond to the number of the amino acid in the human H 1 R.
Site-Directed Mutagenesis. The cDNA encoding the human H 1 R was subcloned in the pAlter plasmid (Promega, Madison, WI), and point mutations were created according to manufacturer's protocol (Altered Sites II; Promega). cDNAs of mutant and wild-type receptors were subcloned into the expression plasmid pcDEF 3 (Goldman et al., 1996) . Sequences were verified by DNA sequencing using the dideoxy chain termination method.
Cell Culture, Transfection, and Membrane Preparation. COS-7 African green monkey kidney cells were maintained at 37°C in a humidified 5% CO 2 , 95% air atmosphere in Dulbecco's modified Eagle's medium containing 50 IU/ml penicillin, 50 g/ml streptomycin, and 10% (v/v) fetal bovine serum. COS-7 cells were transiently transfected using the DEAE-dextran method as described previously (Bakker et al., 2001) , by using 5 g of plasmid DNA per million cells. Two days after transfection, cells were detached by scraping and were harvested by centrifugation. Cell pellets were resuspended in ice-cold water, lysed by repetitive freezing/thawing, and frozen in liquid nitrogen. The obtained crude cell homogenates were stored at Ϫ80°C until further use.
H 1 R Binding Studies. The COS-7 cell homogenates (ϳ5 g) were incubated for 60 min at 30°C in 500 l of binding buffer (50 mM Na 2 /K-phosphate buffer, pH 7.4) containing 3 nM [ 3 H]mepyramine. The nonspecific binding was determined in the presence of 10 M cetirizine. The incubations were stopped by rapid dilution with icecold binding buffer. The bound radioactivity was separated by filtration through Whatman GF/C filters (Whatman, Vel, Belgium) that had been treated with 0.1% polyethylenimine. Filters were washed four times with binding buffer, and radioactivity retained on the filters was measured by liquid scintillation counting.
Molecular Modeling. Our H 1 R homology model was obtained using the bovine rhodopsin crystal structure (Protein Data Bank entry 1L9H; Okada et al., 2002) as the template. Side chains were added using the SCWRL program (Canutescu et al., 2003) . Water molecules present in the rhodopsin structure were retained, and their heavy atoms were kept fixed during all minimizations and molecular dynamic runs. The position of TM3 was manually changed with regard to the rhodopsin structure to avoid a clash between the top of TM3 and TM2 (Lopez-Rodriguez et al., 2002) . Given the presence of the H 1 R-specific Trp 158 (4.56), TM3 could not be put into the position as found by molecular modeling studies on the 5HT 1A receptor. Therefore, we assumed an intermediate position between the location in the crystal structure of rhodopsin and the proposed location in the 5HT 1A receptor model. Short minimization runs were performed (5000 iterations using steepest descent) to refine the initial model. All minimizations were carried out while fixing the C␣ atoms to their initial positions.
Ligands were docked in the wild-type receptor using the automated docking procedure GOLD version 2.1 (Jones et al., 1997) applying default parameters. The complex of the A84S mutant receptor with the ligand was obtained by changing the appropriate residue in the WT receptor-ligand model to its guinea pig homolog. The obtained ligand-receptor complexes were used as input structures for further minimization and molecular dynamic studies. First, the position of the ligand is optimized by fixing the receptor except for the residues involved in ligand binding. Restraints were gradually released before final submission of the resulting complex to two simulated annealing runs at 600 K, each followed by cooling to 200 K before final minimization. In the first round of the simulated annealing run (2500-step initialization, 5000-step production, 5000-step cooling), the C␣ atoms of the receptor are fixed to their position as is the ligand. In the second round (15,000-step production, 5000-step cooling), the ligand is released and free to move. All minimizations and molecular dynamics simulations were performed using Discover (Accelrys, San Diego, CA).
Analytical Methods. Protein concentrations were determined according to Bradford (1976) , using bovine serum albumin as a standard. Binding data were evaluated by a nonlinear, least-squares curve-fitting procedure using GraphPad Prism 4 (GraphPad Software, Inc., San Diego, CA). Obtained pK i , pEC 50 , and K d values are expressed as mean Ϯ S.E.M. of at least three independent experiments. Statistical analyses were carried out by nonpaired Student's t test. P values Ͻ0.05 were considered to indicate a significant difference (P Ͻ 0.05, P Ͻ 0.01, and P Ͻ 0.001). Despite significance, differences in pK i values are only considered relevant when the difference is at least 0.3 logunits.
Results and Discussion

Evaluation of Species Selectivity of H 1 R Ligands. Using displacement of [
3 H]mepyramine binding to guinea pig or human H 1 Rs transiently expressed in COS-7 cells, we determined the affinity of a series of H 1 R antagonists [cetirizine (Zyrtec), ketotifen (Zaditor), loratadine (Claritin), oxatomide (Tinset), fexofenadine (Allegra), astemizole, terfenadine, and mepyramine]. As shown in Fig. 1 , none of the tested H 1 R antagonists (open symbols) showed any preference, i.e., a difference in pK i exceeding 0.3 log units (dotted lines), for binding to the guinea pig H 1 R over the human H 1 R, corroborating recent findings by Seifert et al. (2003) . We also determined the binding affinities of several H 1 R agonists (closed symbols) for both human and guinea pig H 1 Rs. Again, the general rank order of affinities is shared between human and guinea pig H 1 Rs, with histamine having the lowest and the recently characterized partial agonist 8R-lisuride having the highest H 1 R affinity. Considering all tested agonists and antagonists, we observed a linear 
observed between the human and the guinea pig H 1 R for the affinities of the endogenous ligand histamine or the synthetic agonists histaprodifen, 2-(3-trifluoromethylphenyl)histamine, and 8R-lisuride. In contrast, MeHP exhibits a 3-fold higher affinity for the guinea pig H 1 R than for the human H 1 R. For the dimeric compounds HP-HP and HP-HA, the guinea pig over human H 1 R-selectivity is even greater (4-and 10-fold, respectively). The higher affinities of these compounds for the guinea pig H 1 R are in good agreement with the higher potencies of these agonists for guinea pig versus human H 1 Rs as recently demonstrated using a GTPase assay .
The species-dependent pharmacology of several of the histaprodifen analogs is also observed in functional assays. Measuring the effects on the contraction of the guinea pig ileum, HP-HA is up to 50-fold more potent than histamine (Christophe et al., 2003; Seifert et al., 2003) , whereas in assays using heterologously expressed hH 1 Rs, both HP-HA and histamine seem to be equipotent Bruysters et al., 2004) .
Generation and Evaluation of Human H 1 R Mutants. The ligand-binding pocket of aminergic receptors is generally
considered to reside within the TM domains (Shi and Javitch, 2002) . Within these TM domains, several amino acids have been identified in the human and guinea pig H 1 R that are important for the interaction of ligands with the H 1 R: Asp 107 (3.32) in TM3 (Ohta et al., 1994; Moguilevsky et al., 1998; Nonaka et al., 1998; Bruysters et al., 2004) (Leurs et al., 1994 (Leurs et al., , 1995 Ohta et al., 1994; Moguilevsky et al., 1995; Moguilevsky et al., 1998; Bruysters et al., 2004) , and Phe 432 (6.52) and Phe 435 (6.55) in TM6. None of these amino acids differ between human and guinea pig H 1 Rs. Actually, the sequence similarity within these TMs is high (93%), and only 12 amino acids differ between the two proteins ( Fig. 2A) (7.44) in TM7 are predicted to be located either in proximity to the hydrophilic cleft in the hH 1 R or on the interface of two TMs (Fig. 2B) . We therefore reasoned that especially these amino acids may be directly involved in ligand binding and that one of these residues might be responsible for the observed differences in pharmacology between human and guinea pig H 1 Rs. To test this hypothesis, we created the following mutant hH 1 Rs in which the selected amino acids are individually replaced into (Table 2) . Only for mutant hH 1 R Asn 84 Ser (2.61) receptors, which harbor a point mutation in TM2, the affinities for HP-HA are increased (pK i ϭ 6.8) compared with the wild-type hH 1 R (pK i ϭ 6.1), resulting in a gpH 1 R-like (pK i ϭ 7.1) pharmacology ( Fig. 3; Table 2 ). In addition, for HP-HP, the species difference was reversed by the Asn 84 Ser mutation (Table 2) . HP-HA is an agonist for the hH 1 R as measured using a G␣ q/11 -mediated nuclear factor-B reporter gene assay (pEC 50 ϭ 6.4 Ϯ 0.1) with a potency comparable with histamine (pEC 50 ϭ 6.4 Ϯ 0.2) (Bruysters et al., 2004) . For both the gpH 1 R and mutant hH 1 R Asn 84 Ser (2.61), the potency of HP-HA (pEC 50 values of 7.2 Ϯ 0.1 and 7.9 Ϯ 0.1, respectively) strongly exceeds that of histamine (pEC 50 values of 6.0 Ϯ 0.1 and 6.5 Ϯ 0.1, respectively). These findings confirm that also in a functional assay we observe species-specific H 1 R pharmacology, and the mutant hH 1 R Asn 84 Ser not only displays a guinea pig H 1 R binding profile but also a guinea pig H 1 R functional profile.
These data suggest that residue Asn/Ser 84 (2.61) is of critical importance for the observed species-dependent agonist pharmacology of the human and guinea pig H 1 Rs. Moreover, these data also indicate that for some H 1 R agonists TM2 is part of the H 1 R ligand binding-pocket. Interestingly, both human and rat H 1 Rs have an asparagine at position 2.61. Measuring endothelium-dependent relaxation of rat aortic rings, Menghin et al. (2003) have shown that MeHP and HP-HA are equipotent, corroborating our previous findings with human H 1 Rs expressed in COS-7 cells (Bruysters et al., 2004) . However, measuring guinea pig ileum contractions, the potency of HP-HA exceeds that of MeHP 10-fold (Menghin et al., 2003) . These observations further strengthen the involvement of Asn/Ser 84 (2.61) in the species-dependent H 1 R pharmacology. Consequently, pharmacological observations with rat H 1 Rs will have more predictive power for the action of ligands at human H 1 Rs.
Characterization of a Novel, Species-Selective H 1 R Antagonist. The H 1 R species-selective interactions were originally observed for bulky H 1 R agonists (HP-HA and HP-HP). These compounds seem to interact with the "classical" binding pocket (TMs 3, 4, 5, and 6) and Asn/Ser 84 (2.61), hereby defining an additional binding pocket near TM2. To test whether the additional interactions are restricted to agonists alone, or are also possible for antagonists, we screened an in-house library of H 1 R antagonists. From this selection, VUF 4669 was identified as an H 1 R antagonist, which differentiates significantly between human and guinea pig H 1 Rs. VUF 4669 showed a 17-fold increase in binding affinity for the guinea pig H 1 R (pK i ϭ 9.0 Ϯ 0.1), compared with its affinity for the human H 1 R (pK i ϭ 7.7 Ϯ 0.1) ( Table 2) . Apparently, the concept of species-selective binding is not restricted to H 1 R agonists but can also be observed for certain H 1 R antagonists. Again, VUF 4669 exhibits an increased affinity for the mutant hH 1 Asn 84 Ser receptor (pK i ϭ 8.9 Ϯ 0.1), confirming the guinea pig-like pharmacological profile of this mutant human H 1 R. The other human to guinea pig H 1 R mutants used in this study exhibit an affinity for VUF 4669 that is identical to the affinity for the WT human H 1 R (Table 2) .
Previously, also several arpromidine analogs, which display both H 1 R antagonistic and H 2 R agonistic properties, were characterized as guinea pig H 1 R-preferring compounds . Indeed, VUF 8401, a structural analog of arpromidine displays a 9-fold higher affinity for the guinea pig H 1 R than for the human H 1 R (Table 2 ). In addition, VUF 8401 binds with an increased affinity to the mutant hH 1 R Asn 84 Ser (2.61) ( Table 2) , although this mutation did not fully reverse the species difference. None of the other mutant hH 1 Rs show an increased affinity for VUF 8401 (Table 2) . Interaction with Asn/Ser 84 (2.61) therefore partially explains the observed species difference. We hypothesize that for arpromidine-like ligands the higher affinity depends on Ser 84 (2.61) and additional guinea pig H 1 R-specific residues. This hypothesis will be the basis of future investigations.
Like HP-HA and VUF 4669, arpromidine analogs are bulky ligands, having aromatic moieties on either side of a protonated moiety, and we hypothesize that these features are mandatory for species selectivity. H 1 R antagonists such as terfenadine, fexofenadine, and oxatomide, however, also show such features, but they seem not to be species-selective. Clearly, the simple presence of two aromatic domains in a ligand is not the only denominator for species selectivity.
Rationalization of the Role of Asn 84 (2.61) in the Species-Selective Binding. To rationalize the potential role of the amino acid at position 2.61 (Asn/Ser) in the species-selective binding of HP-HA, we created a homology model for the human H 1 R on the basis of the available structural information on bovine rhodopsin (Palczewski et al., 2000; Okada et al., 2002) . In the absence of ligand, our H 1 R homology model suggests hydrogen bonding between Asn 84 (2.61) and Tyr 458 (7.43), a residue that is conserved between human and guinea pig H 1 Rs. Using the automated docking procedure GOLD version 2.1 (Jones et al., 1997) , we subsequently docked the agonist HP-HA in the receptor model (Fig. 4A) . In contrast to H 1 R antagonists such as cetirizine, the diphenyl moiety of HP-HA is not oriented toward TM6, but it is predicted to point toward TMs 1, 2, and 7, confirming our previous suggestions based on site-directed mutagenesis studies of the histamine binding pocket (Bruysters et al., 2004 Ala mutation did also not affect the affinity for histamine (pK i ϭ 4.4 Ϯ 0.2) (Fig. 5) . Because the mutation Tyr 458 Ala would remove potential steric hindrance between HP-HA and the hH 1 R, we expected an increased affinity of HP-HA. Indeed, mutation of Tyr 458 into an alanine results in a 5-fold increase in affinity for HP-HA (pK i ϭ 6.8 Ϯ 0.1) compared with the wild-type H 1 R (Fig. 5) . This affinity is similar to the affinity of HP-HA for both the gpH 1 R (pK i ϭ 7.1 Ϯ 0.1) and the hH 1 R Asn 84 Ser (pK i ϭ 6.8 Ϯ 0.1) ( Table 2) .
The results of our computational and mutagenesis studies indicate an important role of Asn 84 (2.61) as selectivity switch. Moreover, our results illustrate the first structural features of an additional binding pocket between TM2 and TM7 in the H 1 R. Residues in both TM2 and TM7 have been implicated in ligand binding for only a few other aminergic receptors (for review, see Shi and Javitch, 2002) . For example, bulky H 2 R agonists were suggested to interact with TM7 in the H 2 receptor (Kelley et al., 2001) , whereas dopamine D 2 /D 4 receptor subtype selectivity of several classes of antagonists is determined by a hydrophobic microdomain formed by six amino acids in TM2, TM3, and TM7 (including position 2.61) (Javitch et al., 1999) . Also for adrenergic receptors, the key to ␤ 1 /␤ 2 agonist selectivity seems to be localized in TMs 2 and 7 (Isogaya et al., 1999) . Moreover, amino acids present at position 7.43 (homologous to hH 1 R Tyr 458 ) are demonstrated to be involved in ligand binding to 5HT 2A (Roth et al., 1997) and muscarinic acetylcholine M 3 receptors (Wess et al., 1991) . The involvement of TMs 2 and 7 in the H 1 R binding pocket of some H 1 R ligands is therefore highly likely.
Conclusions
In conclusion, the human and guinea pig H 1 Rs exhibit significantly different affinities for agonists, such as HP-HA and HP-HP, as well as for several antagonists such as VUF 4669 and VUF 8401. These differences can be explained by the presence of Asn 84 (2.61) in the hH 1 R versus Ser 84 (2.61) in the gpH 1 R. Based on molecular dynamics simulations and site-directed mutagenesis data, we suggest a possible role for Tyr 458 (7.43) in the binding of certain H 1 R ligands. Our data provide the first evidence that for these H 1 R ligands, TM2 and TM7 are also part of the ligand binding pocket. Exploitation of these additional interaction points within the H 1 R ligand binding pocket in drug development programs may yield a new generation of antihistamines with increased structural diversity compared with the currently known ligands.
